OGI
Organigram Global Inc.
OGI has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over OGI overall, supported by stronger fundamentals and stronger modeled upside.
OGI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Healthy |
OGI's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OGI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.83 | — |
| Cheap | 8x | $3.58 | +331% |
| Fair | 14x | $6.30 | +659% |
| Expensive | 28x | $12.62 | +1421% |
Historical ranges are pointers, not guarantees.
OGI has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OGI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect OGI to return to profit, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OGI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.45 | +$0.45 |
| Q1 2026 | -$0.13 | -360% |
| Q4 2025 | $0.10 | +$0.49 |
| Q3 2025 | -$0.15 | +$0.23 |
| Q2 2025 | -$0.00 | +$0.61 |
| Q2 2024 | -$0.61 | +$1.34 |
| Q2 2023 | -$1.95 | -$1.63 |
| Q1 2023 | -$0.10 | +$0.25 |
OGI has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
OGI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $74.4M | +49% |
| Q1 2026 | $42M | -8.9% |
| Q4 2025 | $44.6M | +49% |
| Q3 2025 | $56.3M | +79% |
| Q2 2025 | $49.8M | +72% |
| Q1 2025 | $46.1M | +74% |
| Q4 2024 | $30M | +17% |
| Q3 2024 | $31.4M | -2.9% |
OGI's revenue is growing: $74M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5% | +8 points |
| Q1 2026 | -16% | -4.8 points |
| Q4 2025 | -5.4% | +11 points |
| Q3 2025 | 1.5% | +0.9 points |
| Q2 2025 | -3% | +9.3 points |
| Q1 2025 | -12% | +29 points |
| Q4 2024 | -16% | +28 points |
| Q3 2024 | 0.6% | +86 points |
OGI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
OGI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -177% |
| Q1 2026 | -$4.9M | +$11.3M |
| Q4 2025 | -$12.7M | -$8.6M |
| Q3 2025 | -$483.7K | -110% |
| Q2 2025 | $3.5M | +$6.9M |
| Q1 2025 | -$16.3M | -$9.4M |
| Q4 2024 | -$4.1M | -194% |
| Q3 2024 | $4.9M | +$21.3M |
OGI has burned cash in almost every quarter: −$21M over the past year, against −$12M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OGI on cash generation, producing positive trailing cash flow while its opponent burns cash.
OGI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +5M shares |
| 1 year | +2% | +2.6M shares |
| 3 years | +71% | +56.6M shares |
| 5 years | +142% | +80.2M shares |
| Available history | +262% | +98.8M shares |
OGI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OGI hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OGI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | -8.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -7.3x | Net Cash |
| Q2 2025 | -7.0x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
| Q4 2022 | -3.9x | Net Cash |
OGI's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over OGI on leverage, with a lower net debt burden relative to earnings.
OGI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 4.9 | Oversold |
OGI's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OGI PE vs Healthcare Sector
| Metric | OGI | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 0 | 29 | 29 pts below |
OGI has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OGI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 12% below |
| 20 week MA | $1.01 | 18% below |
| 50 week MA | $1.26 | 34% below |
| 100 week MA | $1.35 | 39% below |
| 200 week MA | $1.59 | 48% below |
OGI is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OGI on trend strength, trading above more of its moving averages.
OGI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.40 | $5.68 | -40% |
| 2021 | $5.68 | $8.00 | +41% |
| 2022 | $8.00 | $3.12 | -61% |
| 2023 | $3.12 | $1.31 | -58% |
| 2024 | $1.31 | $1.62 | +24% |
| 2025 | $1.62 | $1.79 | +10% |
| 2026 YTD | $1.79 | $0.83 | -54% |
OGI has finished lower in three of the last six years. It's down 54% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OGI on returns for 2026, with the stronger performance.